Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Endocrine Therapy in Early HR+/HER2- Breast Cancer
NCT07581834Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Fujian Medical University Cancer Hospital. Started Jan 2026; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07581834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581834.